Baran Yusuf, Salas Arelis, Senkal Can E, Gunduz Ufuk, Bielawski Jacek, Obeid Lina M, Ogretmen Besim
Department of Biochemistry and Molecular Biology, and Hollings Cancer Center, Ralph H. Johnson Veterans Administration Hospital, and Department of Medicine, Medical University of South Carolina, Charleston 29425, USA.
J Biol Chem. 2007 Apr 13;282(15):10922-34. doi: 10.1074/jbc.M610157200. Epub 2007 Feb 15.
In this study, mechanisms of resistance to imatinib-induced apoptosis in human K562 cells were examined. Continuous exposure to stepwise increasing concentrations of imatinib resulted in the selection of K562/IMA-0.2 and -1 cells, which expressed approximately 2.3- and 19-fold resistance, respectively. Measurement of endogenous ceramides by high performance liquid chromatography/mass spectroscopy showed that treatment with imatinib increased the generation of ceramide, mainly C18-ceramide, which is generated by the human longevity assurance gene 1 (hLASS1), in sensitive, but not in resistant cells. Inhibition of hLASS1 by small interfering RNA partially prevented imatinib-induced cell death in sensitive cells. In reciprocal experiments, overexpression of hLASS1, and not hLASS6, in drug-resistant cells caused a marked increase in imatinib-induced C18-ceramide generation, and enhanced apoptosis. Interestingly, there were no defects in the levels of mRNA and enzyme activity levels of hLASS1 for ceramide generation in K562/IMA-1 cells. However, expression levels of sphingosine kinase-1 (SK1) and generation of sphingosine 1-phosphate (S1P) were increased significantly in K562/IMA-1 cells, channeling sphingoid bases to the sphingosine kinase pathway. The partial inhibition of SK1 expression by small interference RNA modulated S1P levels and increased sensitivity to imatinib-induced apoptosis in resistant cells. On the other hand, forced expression of SK1 in K562 cells increased the ratio between total S1P/C18-ceramide levels approximately 6-fold and prevented apoptosis significantly in response to imatinib. Additional data indicated a role for SK1/S1P signaling in the up-regulation of the Bcr-Abl expression at the post-transcriptional level, which suggested a possible mechanism for resistance to imatinib-mediated apoptosis. In conclusion, these data suggest a role for endogenous C18-ceramide synthesis mainly via hLASS1 in imatinib-induced apoptosis in sensitive cells, whereas in resistant cells, alterations of the balance between the levels of ceramide and S1P by overexpression of SK1 result in resistance to imatinib-induced apoptosis.
在本研究中,我们检测了人K562细胞对伊马替尼诱导凋亡的耐药机制。持续暴露于逐步增加浓度的伊马替尼导致K562/IMA-0.2和-1细胞的产生,它们分别表现出约2.3倍和19倍的耐药性。通过高效液相色谱/质谱法对内源性神经酰胺进行测定,结果显示,伊马替尼处理可增加敏感细胞中神经酰胺的生成,主要是由人类寿命保证基因1(hLASS1)产生的C18-神经酰胺,但耐药细胞中则无此现象。小干扰RNA抑制hLASS1可部分阻止敏感细胞中伊马替尼诱导的细胞死亡。在反向实验中,耐药细胞中hLASS1而非hLASS6的过表达导致伊马替尼诱导的C18-神经酰胺生成显著增加,并增强了细胞凋亡。有趣的是,K562/IMA-1细胞中用于生成神经酰胺的hLASS1的mRNA水平和酶活性水平并无缺陷。然而,K562/IMA-1细胞中鞘氨醇激酶-1(SK1)的表达水平和1-磷酸鞘氨醇(S1P)的生成显著增加,使鞘氨醇碱基进入鞘氨醇激酶途径。小干扰RNA对SK1表达的部分抑制可调节S1P水平,并增加耐药细胞对伊马替尼诱导凋亡的敏感性。另一方面,K562细胞中SK1的强制表达使总S1P/C18-神经酰胺水平的比值增加了约6倍,并显著阻止了对伊马替尼的凋亡反应。其他数据表明,SK1/S1P信号在转录后水平对Bcr-Abl表达的上调中起作用,这提示了对伊马替尼介导的凋亡产生耐药的一种可能机制。总之,这些数据表明,内源性C18-神经酰胺主要通过hLASS1的合成在敏感细胞的伊马替尼诱导凋亡中起作用,而在耐药细胞中,SK1的过表达导致神经酰胺和S1P水平之间平衡的改变,从而导致对伊马替尼诱导凋亡的耐药。